Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion for the company’s Sogroya therapy.
The once-weekly treatment – also known as somapacitan – is for the replacement of endogenous growth hormone (GH) in aged children three years and older. It can also be used to treat adolescents with growth failure due to growth hormone deficiency.
The positive opinion has emerged following data from Novo Nordisk’s phase 3 ‘REAL4’ trial, which demonstrated that a once-weekly subcutaneous injection of Sogroya worked as effectively as a daily injection of Norditropin.
By the conclusion of the trial period, prepubertal children who were treated with once-weekly Sogroya had achieved similar growth as children who were treated with Norditropin.
Martin Holst Lange, executive vice president for development at Novo Nordisk, was optimistic about the verdict: “Today’s positive CHMP opinion is a step forward to reducing the impact of growth hormone deficiency for children, adolescents and their families in Europe.”
He added: “We are hopeful that Sogroya will help improve the lives of children as young as three years old by offering a simpler treatment option with fewer injections in an easy-to-use device, whilst helping them to achieve their growth targets.”
Meanwhile, the European Commission (EC) will review the CHMP’s positive opinion and a final decision on marketing authorisation is expected later in the year. If approved, Sogroya will be available across some European countries by the end of 2023.
Growth hormone deficiency is a rare disease and a treatable cause of short stature – it is thought to impact around one in 3,500 to 10,000 children.
by John Pinching
Source: pharmatimes.com
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
